MLR3 molecule is an activation antigen shared by human B, T lymphocytes and T cell precursors
β Scribed by Angela Risso; Maria Elisabetta Cosulich; Anna Rubartelli; Maria Rosaria Mazza; Antonio Bargellesi
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 714 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
β¦ Synopsis
MLR3 molecule is an activation antigen shared by human B, T lymphocytes and T cell precursors*
MLR3 molecule is a membrane glycoprotein (mol. mass range 28-34 kDa) present on activated, but not resting human peripheral T cells, B cells and thymocytes. Its kinetics of appearance on the cell surface (3 h after the addition of the inductive signal to the cells) suggests that it is an early activation antigen. The proliferative response of cultured T and B lymphocytes and thymocytes to different activation signals is inhibited by the addition of MLR3 monoclonal antibody. Moreover the antibody in combination with non-mitogenic doses of phorbol myristate acetate leads to proliferation of thymocytes and resting B and T lymphocytes. In the latter, synthesis of interleukin 2 is also induced. Biochemical analysis of MLR3 antigen indicates that it is a phosphorylated protein with N-linked sugar moieties. Together these data suggest a role for MLR3 antigen in the signal transduction process during activation, both for mature lymphocytes and for T cell precursors.
π SIMILAR VOLUMES
## Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes To identify the ligand for the B cell-associated antigen CD40, we constructed a chimeric immunoglobulin molecule where the extracellular porti
## Anti -CD3 Ψ anti-B-cell antigen bispecific monoclonal antibodies (bsAbs) can redirect T-cell-mediated lysis toward malignant B cells. Clinical trials with CD3-based bsAbs have shown toxicity in patients which is likely related to nonspecific T-cell activation and targeting. Our current studies